• News

    Department of Defense Armed Forces Institute of Regenerative Medicine – II (AFIRM II)

    Date: April 24, 2012

    This program funds basic through translational regenerative medicine research and development. Activities acceptable under this award may include basic scientific research, development of animal models, preclinical studies required for initiation of FDA-regulated human clinical trials, and Phase I – II human clinical trials. Read more.